Boardroom Alpha
Meeting calendar
IRLA · Annual meeting · Thursday, June 11, 2026

Irulya Therapeutics Inc

1 nominee · 5 ballot items.

Elect one Class I director (June Bray); approve an amendment to effect a reverse stock split of common stock at a ratio between 1-for-10 and 1-for-100 with the board setting the exact ratio; ratify BDO USA, P.C. as independent auditors for 2026; approve, on an advisory basis, the compensation of the named executive officers; and approve adjournment/postponement of the Annual Meeting if needed to solicit additional votes.

Market cap
$405M
1Y TSR
-91.4%
Board grade
C
Record date
Apr 23, 2026
Filing
DEF 14A
Meeting concluded · Jun 11, 2026

Follow how the vote landed and what changed on Irulya Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot5

  1. 1

    Election of Class I Director (June Bray

    ManagementBoard: FOR

    Elect June Bray as Class I director to serve until the 2029 annual meeting and until her successor is duly elected and qualified.

  2. 2

    Approval of Amendment to Our Certificate of Incorporation to Effect a Reverse Stock Split of the Issued and Outstanding Common Stock

    ManagementBoard: FOR

    Approve an amendment to the Certificate of Incorporation to permit a reverse stock split of outstanding common stock at a ratio ranging from 1-for-10 to 1-for-100, with the Board authorized to set the exact ratio within that range without further stockholder approval and to implement the split within one year if it deems appropriate.

    More detail

    This management proposal requests stockholder approval to amend the Certificate of Incorporation authorizing the Board to effect a reverse stock split of issued and outstanding common stock at a ratio between 1-for-10 and 1-for-100, with the Board retaining sole discretion to choose the exact ratio within that range and up to one year to implement the split. Management is pursuing this authorization primarily to address Nasdaq listing concerns: the company received notices for failing to meet the $1.00 minimum bid price and a low market value of listed securities, and although it previously effected a 1-for-10 split (April 10, 2026), the Board believes a broader authorization provides flexibility to regain and sustain compliance. The proposal is transaction-focused rather than operational — it does not change authorized share counts or par value but will reduce outstanding shares and proportionately adjust warrants, options, RSUs and plan reserves. The Board emphasizes that the split would not change stockholders’ proportional ownership except for fractional-share treatment, and that fractional shares would be addressed by rounding rules described in the filing. Material risks include potential adverse effects on liquidity and market capitalization if the post-split price falls, the possibility that the split alone will not resolve Nasdaq MVLS compliance, and the potential anti-takeover consequence of increasing authorized-but-unissued shares relative to outstanding shares. Management also notes administrative impacts — adjustments to exercise prices, amended plan reserves, and tax/accounting considerations — and reserves the right to abandon the split even after authorization. Overall, the Board recommends FOR the amendment on grounds that it is a prudent means to preserve Nasdaq listing, improve marketability, and retain strategic flexibility while noting that the measure is not guaranteed to improve long-term shareholder value and could have unintended liquidity or market-capitalization effects.

  3. 3

    Ratification of Selection of Independent Registered Public Accounting Firm (BDO USA, P.C.

    ManagementBoard: FOR

    Ratify the audit committee’s selection of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

  4. 4

    Advisory Vote on the Compensation of the Named Executive Officers (Say-on-Pay

    ManagementBoard: FOR

    Advisory (non-binding) approval of the compensation of the Company’s named executive officers as disclosed in the proxy statement, including compensation tables and narrative discussion.

    More detail

    This is a non-binding, advisory ‘say-on-pay’ proposal required under Dodd-Frank and SEC rules, asking stockholders to approve the Company’s disclosed executive compensation policies and amounts for the named executive officers. Management requests a FOR vote to indicate shareholder support for the compensation structure described, which combines base salary, annual performance bonuses tied to corporate and individual objectives, and long-term equity incentives; the Board states it will consider the vote outcome when making future compensation determinations. The vote has no legal force but is a governance signal that can influence compensation committee behavior; a negative vote would likely trigger engagement between the Board/compensation committee and major holders, and could lead to changes in pay design or disclosure. The Company has disclosed target bonus percentages, the structure of equity grants, severance/change-in-control arrangements, and clawback/401(k) practices — factors institutional investors commonly evaluate. Given the firm’s operational context (Nasdaq compliance pressures and strategic options under consideration), the compensation program is presented as intended to retain executives and align incentives with corporate milestones; shareholders should weigh realized pay versus company performance. Management’s commitment to consider results gives the proposal practical significance despite its advisory nature.

  5. 5

    Adjournment or Postponement of the Annual Meeting

    ManagementBoard: FOR

    Authorize the chairman to adjourn or postpone the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in favor of the other proposals.

    More detail

    This management proposal seeks authority for the meeting chairman to adjourn or postpone the Annual Meeting to allow additional time to solicit proxies if one or more proposals lack sufficient votes for approval. It is a routine, procedural measure designed to avoid the need for a second meeting or rushed decision-making and to enable the company to seek additional shareholder engagement if vote thresholds are not met. The adjournment authority typically allows management to extend solicitation efforts (mail, telephone, electronic) and to address broker non-votes or other shortfalls, especially on non-routine items. Although discretionary adjournment can delay resolution of matters and impose costs, it preserves the company’s ability to obtain shareholder approval without reconvening a new meeting, which could be more expensive and time consuming. Because the proposal is presented only if needed, its effect is conditional and usually uncontroversial; brokers are permitted to vote on routine adjournments in many cases, which can mitigate vote shortfalls. The Board recommends approval to retain flexibility and proceed prudently if further solicitation is warranted.

Director elections

Nominees on the ballot1

Independent
Tenure on this board
4.3 yrs
Ownership

Top institutional holders10

Latest 13F quarter
1Ikarian Capital, LLC7.1%72,251$1M
2MILLENNIUM MANAGEMENT LLC7.0%70,779$1M
3BALYASNY ASSET MANAGEMENT L.P.6.9%69,967$13M
4Squadron Capital Management LLC4.0%40,375$734K
5Shay Capital LLC1.7%17,468$329K
6BOOTHBAY FUND MANAGEMENT, LLC1.4%13,911$253K
7VANGUARD CAPITAL MANAGEMENT LLC1.2%12,044$219K
8JANE STREET GROUP, LLC0.7%7,133$130K
9JANE STREET GROUP, LLC0.5%5,509$100K
10Cormorant Asset Management, LP0.5%5,498$100K
Filings

Irulya Therapeutics Inc proxy statements and SEC reports

Annual & quarterly reports (10-K, 10-Q)
Proxy statements (DEF 14A)
Reference

Frequently asked questions

When is the Irulya Therapeutics Inc 2026 annual meeting?
Irulya Therapeutics Inc (IRLA) holds its 2026 annual shareholder meeting on Thursday, June 11, 2026.
What is the record date for the Irulya Therapeutics Inc 2026 meeting?
The record date for the Irulya Therapeutics Inc 2026 meeting is Thursday, April 23, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Irulya Therapeutics Inc's 2026 meeting?
The board is presenting 1 director nominee at the Irulya Therapeutics Inc 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Irulya Therapeutics Inc 2026 meeting?
Shareholders will vote on 5 proposals at the Irulya Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer